Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT
In this prospective study (NCT01595295), 272 patients treated with azacitidine completed 1456 EuroQol 5-Dimension (EQ-5D) questionnaires. Linear mixed-effect modelling was used to incorporate longitudinal data. When compared with a matched reference population, myeloid patients reported more pronounced restrictions in usual activities (+28%, p < 0.0001), anxiety/depression (+21%, p < 0.0001), selfcare (+18%, p < 0.0001) and mobility (+15%, p < 0.0001), as well as lower mean EQ-5D-5L indices (0.81 vs. 0.88, p < 0.0001), and lower self-rated health on the EuroQol Visual Analogue Scale (EQ-VAS) (64 vs. 72%, p < 0.0001). After multivariate-adjustment, (i) the EQ-5D-5L index assessed at azacitidine start the predicted time with clinical benefit (TCB) (9.6 vs. 6.6 months; p = 0.0258; HR = 1.43), time to next treatment (TTNT) (12.8 vs. 9.8 months; p = 0.0332; HR = 1.42) and overall survival (OS) (17.9 vs. 12.9 months; p = 0.0143; HR = 1.52); (ii) Level Sum Score (LSS) predicted azacitidine response (p = 0.0160; OR = 0.451) and the EQ-5D-5L index showed a trend (p = 0.0627; OR = 0.522); (iii) up to 1432 longitudinally assessed EQ-5D-5L response/clinical parameter pairs revealed significant associations of EQ-5D-5L response parameters with haemoglobin level, transfusion dependence and hematologic improvement. Significant increases of the likelihood ratios were observed after addition of LSS, EQ-VAS or EQ-5D-5L-index to the International Prognostic Scoring System (IPSS) or the revised IPSS (R-IPSS), indicating that they provide added value to these scores.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cancers - 15(2023), 5 vom: 22. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pleyer, Lisa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 13.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers15051388 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354058169 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354058169 | ||
| 003 | DE-627 | ||
| 005 | 20231226061413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers15051388 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354058169 | ||
| 035 | |a (NLM)36900181 | ||
| 035 | |a (PII)1388 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pleyer, Lisa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMT |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a In this prospective study (NCT01595295), 272 patients treated with azacitidine completed 1456 EuroQol 5-Dimension (EQ-5D) questionnaires. Linear mixed-effect modelling was used to incorporate longitudinal data. When compared with a matched reference population, myeloid patients reported more pronounced restrictions in usual activities (+28%, p < 0.0001), anxiety/depression (+21%, p < 0.0001), selfcare (+18%, p < 0.0001) and mobility (+15%, p < 0.0001), as well as lower mean EQ-5D-5L indices (0.81 vs. 0.88, p < 0.0001), and lower self-rated health on the EuroQol Visual Analogue Scale (EQ-VAS) (64 vs. 72%, p < 0.0001). After multivariate-adjustment, (i) the EQ-5D-5L index assessed at azacitidine start the predicted time with clinical benefit (TCB) (9.6 vs. 6.6 months; p = 0.0258; HR = 1.43), time to next treatment (TTNT) (12.8 vs. 9.8 months; p = 0.0332; HR = 1.42) and overall survival (OS) (17.9 vs. 12.9 months; p = 0.0143; HR = 1.52); (ii) Level Sum Score (LSS) predicted azacitidine response (p = 0.0160; OR = 0.451) and the EQ-5D-5L index showed a trend (p = 0.0627; OR = 0.522); (iii) up to 1432 longitudinally assessed EQ-5D-5L response/clinical parameter pairs revealed significant associations of EQ-5D-5L response parameters with haemoglobin level, transfusion dependence and hematologic improvement. Significant increases of the likelihood ratios were observed after addition of LSS, EQ-VAS or EQ-5D-5L-index to the International Prognostic Scoring System (IPSS) or the revised IPSS (R-IPSS), indicating that they provide added value to these scores | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Austrian Registry of Hypomethylating Agents | |
| 650 | 4 | |a EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) | |
| 650 | 4 | |a acute myeloid leukaemia | |
| 650 | 4 | |a azacitidine | |
| 650 | 4 | |a chronic myelomonocytic leukaemia | |
| 650 | 4 | |a health-related quality of life (HRQoL) | |
| 650 | 4 | |a mixed-effects linear models | |
| 650 | 4 | |a myelodysplastic syndromes | |
| 650 | 4 | |a patient-reported outcome (PRO) | |
| 650 | 4 | |a prognosis | |
| 700 | 1 | |a Heibl, Sonja |e verfasserin |4 aut | |
| 700 | 1 | |a Tinchon, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Vallet, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Schreder, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Melchardt, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Stute, Norbert |e verfasserin |4 aut | |
| 700 | 1 | |a Föhrenbach Quiroz, Kim Tamara |e verfasserin |4 aut | |
| 700 | 1 | |a Leisch, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Egle, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Scagnetti, Lukas |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Dominik |e verfasserin |4 aut | |
| 700 | 1 | |a Beswick, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Drost, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Larcher-Senn, Julian |e verfasserin |4 aut | |
| 700 | 1 | |a Grochtdreis, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Vaisband, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Hasenauer, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Zaborsky, Nadja |e verfasserin |4 aut | |
| 700 | 1 | |a Greil, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Stauder, Reinhard |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 15(2023), 5 vom: 22. Feb. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:5 |g day:22 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers15051388 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 5 |b 22 |c 02 | ||